Progabide
Progabide Basic information
- Product Name:
- Progabide
- Synonyms:
-
- progabide
- BUTANAMIDE, 4-[[(4-CHLOROPHENYL)(5-FLUORO-2-HYDROXYPHENYL)METHYLENE]AMINO]-
- Halogabide
- (E)-4-((4-chlorophenyl)(5-fluoro-2-hydroxyphenyl)methyleneamino)butanamide
- 4-[[(Z)-(4-Chlorophenyl)-(3-fluoro-6-oxo-1-cyclohexa-2,4-dienylidene)methyl]amino]butanamide
- 4-[[(4-Chlorophenyl)(5-fluoro-2hydroxyphenyl)methylene]amino]butanamide
- C-abren(e)
- SL-76．002
- CAS:
- 62666-20-0
- MF:
- C17H16ClFN2O2
- MW:
- 334.77
- EINECS:
- 263-679-4
- Product Categories:
-
- Amines
- Aromatics
- Intermediates & Fine Chemicals
- Pharmaceuticals
- Mol File:
- 62666-20-0.mol
Progabide Chemical Properties
- Melting point:
- 133-135°; mp 142.5° (Kaplan, J. Med. Chem.)
- Boiling point:
- 525.4±50.0 °C(Predicted)
- Density
- 1.2822 (estimate)
- storage temp.
- 2-8°C
- solubility
- Chloroform (Slightly, Sonicated), DMSO, Methanol (Slightly, Sonicated)
- form
- Solid
- pka
- pKa 3.41 ± 0.04(0.4% MeOH,t=37,Iundefined)(Approximate)
- color
- Light Yellow to Yellow
- Water Solubility
- 37.16mg/L(37 ºC)
- CAS DataBase Reference
- 62666-20-0
Progabide Usage And Synthesis
Description
Progabide is a broad-spectrum anticonvulsant agent indicated for the treatment of a wide variety of seizure disorders. Synthesized as a GABA-prodrug, anticonvulsant activity appears due to the parent drug and its acid metabolite, as well as to GABAmide and GABA liberated therefrom.
Chemical Properties
Bright Yellow Solid
Originator
Synthelabo (France)
Uses
Progabide is a gamma-aminobutyric acid (GABA) antagonist with antiepileptic activity.
Definition
ChEBI: Progabide is a diarylmethane.
brand name
Gabren (Synthelabo Pharmacie, France);Gabaphore;Sl 76 002;GABRENE.
World Health Organization (WHO)
Progabide, an anticonvulsant, was introduced in France in 1985 for the treatment of epilepsy. Its use has occasionally been associated with clinically evident signs of icteric hepatitis developing within the first six months of treatment. These signs are generally reversible on withdrawal of the drug but continuation of treatment has been associated with three reported fatalities (two of which are doubtfully related to the drug). The manufacturer revised the data sheet in March 1986 advising that use of progabide should be reserved for patients unresponsive to other anticonvulsants.
Progabide Preparation Products And Raw materials
Raw materials
ProgabideSupplier
- Tel
- 010-82848833 400-666-7788
- jkinfo@jkchemical.com
- Tel
- +86 (0) 571 85 58 67 18
- sales@capotchem.com
- Tel
- 021-50135380
- shchemsky@sina.com
- Tel
- 010-56205725
- waley188@sohu.com
- Tel
- 021-QQ：65489617 15618227136
- Sales@ATKchemical.com